AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31125171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermocosmetic treatments
Number of subjects: 36
Study 31125171 — intervention group
Group type: COMPARATOR
Intervention: French skin
Number of subjects: 36
Study 31125171 — intervention group
Group type: COMPARATOR
Intervention: Brazilian skin
Number of subjects: 36
Study 31307211 — intervention group
Group type: COMPARATOR
Intervention: Single Anesthetic (SA) - bupivacaine
Number of subjects: 80
Study 31307211 — intervention group
Group type: EXPERIMENTAL
Intervention: Three Additives (TA) - bupivacaine with buprenorphine, clonidine, and dexamethasone
Number of subjects: 80
Study 31307211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SA and TA
Number of subjects: 80
Study 28404623 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve-guided complete revascularization
Number of subjects: 627
Study 28404623 — intervention group
Group type: COMPARATOR
Intervention: Infarct-related percutaneous coronary intervention only
Number of subjects: 627
Study 25854575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime
Number of subjects: 63
Study 25854575 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone sodium (Control)
Number of subjects: 63
Study 23812462 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vaginal dilator use from postoperative weeks 4 through 8
Number of subjects: 60
Study 23812462 — intervention group
Group type: COMPARATOR
Intervention: No dilator use (Control)
Number of subjects: 60
Study 23812462 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sexual function and Patient Global Impression of Improvement scores
Number of subjects: 60
Study 21168339 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure (HP: 80-90 mm Hg)
Number of subjects: 92
Study 21168339 — intervention group
Group type: COMPARATOR
Intervention: Low-pressure (LP: 60-70 mm Hg)
Number of subjects: 92
Study 19583607 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm of methylprednisolone before CPB
Number of subjects: 30
Study 19583607 — intervention group
Group type: COMPARATOR
Intervention: Standard coronary bypass surgery without any additional medication (Control)
Number of subjects: 30
Study 17210899 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar puncture to assess intracranial pressure (ICP)
Number of subjects: 0
Study 15037052 — intervention group
Group type: EXPERIMENTAL
Intervention: Confabulations of the patient (ES)
Number of subjects: 1
Study 15630352 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for high-risk patients
Number of subjects: 0
Study 15630352 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and radiotherapy for muscle-invasive bladder cancer
Number of subjects: 0
Study 15630352 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy for metastatic disease
Number of subjects: 0
Study 15630352 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality treatment options (operation, chemotherapy, radiotherapy, biology therapy)
Number of subjects: 0
Study 10037207 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (50 mg BID for 3 days)
Number of subjects: 35
Study 10037207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 10037207 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 35
Study 8746921 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dosing of 8 mg sublingual buprenorphine
Number of subjects: 99
Study 8746921 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day dosing of 8 mg sublingual buprenorphine
Number of subjects: 99
Study 2286597 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg i.v. ofloxacin per day
Number of subjects: 60
Study 2286597 — intervention group
Group type: COMPARATOR
Intervention: 3 x 4000 mg piperacillin per day
Number of subjects: 60
Study 7018639 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of glucagon intravenously
Number of subjects: 91
Study 7018639 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 91
Study 31122037 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention with Advance Care Planning (ACP) education, including interactive decisional support, emotional support, and barrier navigation.
Number of subjects: 0
Study 31122037 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) receiving ACP education alone.
Number of subjects: 0
Study 30180880 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational agent with high self-awareness
Number of subjects: 900
Study 30180880 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational agent with low self-awareness
Number of subjects: 900
Study 30180880 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition with high self-awareness
Number of subjects: 900
Study 30180880 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition with low self-awareness
Number of subjects: 900
Study 27316539 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based home health education and blood pressure monitoring by trained female community health volunteers.
Number of subjects: 1638
Study 27316539 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 1638
Study 24600660 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF-BB + β-TCP
Number of subjects: 36
Study 24600660 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTG
Number of subjects: 36
Study 24600660 — intervention group
Group type: COMPARATOR
Intervention: CPF
Number of subjects: 36
Study 22724387 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 870
Study 22724387 — intervention group
Group type: COMPARATOR
Intervention: Other anti-epileptic drugs
Number of subjects: 870
Study 22724387 — intervention group
Group type: COMPARATOR
Intervention: Migraineurs
Number of subjects: 870
Study 22724387 — intervention group
Group type: COMPARATOR
Intervention: Epileptics
Number of subjects: 870
Study 22724387 — intervention group
Group type: COMPARATOR
Intervention: Diabetics
Number of subjects: 870
Study 22724387 — intervention group
Group type: COMPARATOR
Intervention: Random sample
Number of subjects: 870
Study 20137764 — intervention group
Group type: COMPARATOR
Intervention: Fasted condition (0% fat)
Number of subjects: 12
Study 20137764 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat meal (200-300 kcal, ~6% fat)
Number of subjects: 12
Study 20137764 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-fat meal (500-600 kcal, ~30% fat)
Number of subjects: 12
Study 20137764 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (1,000 kcal, ~50% fat)
Number of subjects: 12
Study 18048611 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Magazine
Number of subjects: 357
Study 18048611 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking Magazine
Number of subjects: 357
Study 16238275 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of Dexamethasone every 12 hours for two doses (Group C, n=10)
Number of subjects: 20
Study 16238275 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group T, n=10)
Number of subjects: 20
Study 12405303 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolytic coeliac plexus block
Number of subjects: 30
Study 10096580 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-IFN-alpha vaccine
Number of subjects: 242
Study 10096580 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 242
Study 7759711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (n = 54)
Number of subjects: 176
Study 7759711 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide (n = 73)
Number of subjects: 176
Study 7759711 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine/mexiletine (n = 49)
Number of subjects: 176
Study 7759711 — intervention group
Group type: COMPARATOR
Intervention: ESVEM protocol (compared to standard protocol)
Number of subjects: 176
Study 31953844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MF)
Number of subjects: 24
Study 31953844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindlessness meditation (ML)
Number of subjects: 24
Study 31953844 — intervention group
Group type: COMPARATOR
Intervention: Control (CO)
Number of subjects: 24
Study 30452125 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA (propofol and remifentanil infusion)
Number of subjects: 80
Study 30452125 — intervention group
Group type: COMPARATOR
Intervention: DES (desflurane inhalation and remifentanil infusion)
Number of subjects: 80
Study 30452125 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA
Number of subjects: 80
Study 28086244 — intervention group
Group type: EXPERIMENTAL
Intervention: Midvastus approach
Number of subjects: 84
Study 28086244 — intervention group
Group type: COMPARATOR
Intervention: Medial parapatellar approach
Number of subjects: 84
Study 28086244 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 84
Study 26279108 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused cardiac ultrasound (FCU) assessment of inferior vena cava (IVC) size and collapsibility.
Number of subjects: 95
Study 26279108 — intervention group
Group type: EXPERIMENTAL
Intervention: FCU IVC imaging categorization (normal, intermediate, plethoric IVCs).
Number of subjects: 95
Study 26279108 — intervention group
Group type: COMPARATOR
Intervention: Clinical bedside assessment of volume status.
Number of subjects: 95
Study 23262204 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of temsirolimus (25 mg IV weekly) and bevacizumab (10 mg/kg every other week)
Number of subjects: 49
Study 23262204 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of temsirolimus and bevacizumab
Number of subjects: 49
Study 21251162 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 1040
Study 19692044 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone (experimental group 2)
Number of subjects: 63
Study 19692044 — intervention group
Group type: COMPARATOR
Intervention: Emollient cream (placebo group 1)
Number of subjects: 63
Study 19692044 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical triamcinolone (nonblinded treatment for nonresponders)
Number of subjects: 63
Study 19692044 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 63
Study 16469977 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein breakfast (HP)
Number of subjects: 15
Study 16469977 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate breakfast (HC)
Number of subjects: 15
Study 14763724 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise programme (2 sessions per week, 1 hour duration)
Number of subjects: 106
Study 14763724 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise programme
Number of subjects: 106
Study 14763724 — intervention group
Group type: COMPARATOR
Intervention: Control group (monthly education material and quarterly telephone calls)
Number of subjects: 106
Study 14763724 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 10707876 — intervention group
Group type: EXPERIMENTAL
Intervention: TTV-A primer set
Number of subjects: 171
Study 10707876 — intervention group
Group type: EXPERIMENTAL
Intervention: TTV-B primer set
Number of subjects: 171
Study 10707876 — intervention group
Group type: EXPERIMENTAL
Intervention: Either/both primer sets
Number of subjects: 171
Study 10707876 — intervention group
Group type: COMPARATOR
Intervention: Demographic, biochemical, virologic, and histologic scores
Number of subjects: 171
Study 9492396 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite stimulation package (STIM)
Number of subjects: 432
Study 9492396 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional management (NUT)
Number of subjects: 432
Study 9492396 — intervention group
Group type: COMPARATOR
Intervention: Control group from high socioeconomic status (Control I)
Number of subjects: 432
Study 9492396 — intervention group
Group type: COMPARATOR
Intervention: Control group from low socioeconomic status (Control II)
Number of subjects: 432
Study 9492396 — intervention group
Group type: EXPERIMENTAL
Intervention: Community study interventions (STIM or NUT)
Number of subjects: 432
Study 8366464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimics with depression
Number of subjects: 0
Study 8366464 — intervention group
Group type: COMPARATOR
Intervention: Bulimics without depression
Number of subjects: 0
Study 8366464 — intervention group
Group type: COMPARATOR
Intervention: Depressed patients without bulimia
Number of subjects: 0
Study 8366464 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients with bulimia
Number of subjects: 0
Study 3019810 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day mebeverine
Number of subjects: 120
Study 3019810 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/day wheat bran
Number of subjects: 120
Study 3019810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31648665 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine 2% with epinephrine 1:100,000
Number of subjects: 65
Study 31648665 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered lidocaine 2% with epinephrine 1:100,000
Number of subjects: 65
Study 28107891 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive behavioral stress management (T-CBSM), N=56
Number of subjects: 100
Study 28107891 — intervention group
Group type: EXPERIMENTAL
Intervention: Live cognitive behavioral stress management (L-CBSM), N=44
Number of subjects: 100
Study 26108771 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective appendicostomy
Number of subjects: 74
Study 26108771 — intervention group
Group type: COMPARATOR
Intervention: Traditional ileostomy
Number of subjects: 74
Study 23184666 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide (1 mg) with food/caffeine (standardized breakfast including two cups of coffee)
Number of subjects: 35
Study 23184666 — intervention group
Group type: COMPARATOR
Intervention: Anagrelide (1 mg) in a fasted state
Number of subjects: 35
Study 21849264 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg weekly
Number of subjects: 36
Study 21849264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18381881 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump bypass surgery
Number of subjects: 0
Study 18381881 — intervention group
Group type: COMPARATOR
Intervention: Conventional bypass grafting
Number of subjects: 0
Study 16522932 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-cyclodextrin (GCD)
Number of subjects: 32
Study 14528202 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar coagulation
Number of subjects: 99
Study 14528202 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (combination heat probe coagulation and injection therapy)
Number of subjects: 99
Study 10928231 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 13
Study 10928231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8826542 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg d-amphetamine (AMP)
Number of subjects: 40
Study 8826542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1418277 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (Hypnomidate)
Number of subjects: 0
Study 1418277 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (Trapanal)
Number of subjects: 0
Study 3908332 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 20
Study 3908332 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 20
Study 29166771 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (16 weeks)
Number of subjects: 90
Study 29166771 — intervention group
Group type: COMPARATOR
Intervention: Yoga (8 weeks after crossover)
Number of subjects: 90
Study 28719494 — intervention group
Group type: EXPERIMENTAL
Intervention: Hockey FIT (intervention group)
Number of subjects: 80
Study 28719494 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (comparator group)
Number of subjects: 80
Study 27116867 — intervention group
Group type: EXPERIMENTAL
Intervention: KinesioTaping
Number of subjects: 60
Study 23587660 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean pear juice
Number of subjects: 14
Study 20456545 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate + red-light
Number of subjects: 48
Study 20456545 — intervention group
Group type: COMPARATOR
Intervention: Placebo + red-light
Number of subjects: 48
Study 18476313 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational tobacco intervention
Number of subjects: 74
Study 18476313 — intervention group
Group type: COMPARATOR
Intervention: Brief advice/care as usual
Number of subjects: 74
Study 16581897 — intervention group
Group type: EXPERIMENTAL
Intervention: Open suctioning method
Number of subjects: 18
Study 16581897 — intervention group
Group type: COMPARATOR
Intervention: Closed suctioning method
Number of subjects: 18
Study 15362251 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 7
Study 15362251 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen and progesterone therapy
Number of subjects: 7
Study 15362251 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid therapy
Number of subjects: 7
Study 15362251 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexanoic acid
Number of subjects: 7
Study 15362251 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 7
Study 11687774 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity physical activity (75% VO2max)
Number of subjects: 21
Study 11687774 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity physical activity (45% VO2max)
Number of subjects: 21
Study 11687774 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity (60% VO2max)
Number of subjects: 21
Study 11687774 — intervention group
Group type: COMPARATOR
Intervention: Zero resistance (control)
Number of subjects: 21
Study 9137847 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium 500 mg
Number of subjects: 176
Study 9137847 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium 1000 mg
Number of subjects: 176
Study 9137847 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium 1500 mg
Number of subjects: 176
Study 9137847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 7933515 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipurpose pulmonary artery catheter (PAC)
Number of subjects: 20
Study 7933515 — intervention group
Group type: EXPERIMENTAL
Intervention: A-V paceport PAC
Number of subjects: 20
Study 3137036 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pefloxacin b.i.d.
Number of subjects: 42
Study 3137036 — intervention group
Group type: COMPARATOR
Intervention: 160/800 mg cotrimoxazole b.i.d.
Number of subjects: 42
Study 29901829 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management barriers (measured by PRISM; scaled 1 to 5)
Number of subjects: 267
Study 29901829 — intervention group
Group type: EXPERIMENTAL
Intervention: Denial of Disease and Its Consequences
Number of subjects: 267
Study 29901829 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen Pain and Bother
Number of subjects: 267
Study 29901829 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding and Organizing Care
Number of subjects: 267
Study 28005920 — intervention group
Group type: EXPERIMENTAL
Intervention: Vita Mamba (fortified peanut butter snack) and deworming
Number of subjects: 321
Study 28005920 — intervention group
Group type: COMPARATOR
Intervention: Control group (deworming only)
Number of subjects: 321
Study 25100424 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive care smoking cessation intervention
Number of subjects: 2271
Study 25100424 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2271
Study 23056012 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 142
Study 23056012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 21280316 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CA-125 levels measured by electrochemiluminescence immunization assay
Number of subjects: 200
Study 21280316 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CA-125 levels
Number of subjects: 200
Study 18461609 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir/lamivudine combination therapy
Number of subjects: 8
Study 18461609 — intervention group
Group type: COMPARATOR
Intervention: Adefovir monotherapy
Number of subjects: 8
Study 15855323 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 25
Study 15855323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12648318 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study 12648318 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (placebo)
Number of subjects: 0
Study 11204387 — intervention group
Group type: EXPERIMENTAL
Intervention: Port-Access mitral valve surgery (group A, n=14)
Number of subjects: 31
Study 11204387 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified technique for Port-Access mitral valve surgery (group B, n=17)
Number of subjects: 31
Study 11204387 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results of Port-Access mitral valve surgery
Number of subjects: 31
Study 8867431 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoteridol (0.1 mmol/kg bodyweight)
Number of subjects: 20
Study 8867431 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoteridol (0.3 mmol/kg bodyweight)
Number of subjects: 20
Study 8867431 — intervention group
Group type: COMPARATOR
Intervention: Gadoteridol (0.1 and 0.3 mmol/kg bodyweight)
Number of subjects: 20
Study 8867431 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine
Number of subjects: 20
Study 1506600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovasoprotective diet
Number of subjects: 463
Study 1506600 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 463